PI-88

Phase 3Small molecule

CCellxpert Biotechnology Corp.

PI-88 is one of 196 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

195

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

HepatitisActive, not recruiting

Metastatic MelanomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

HepatitisPhase 3

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PI-88

CCellxpert Biotechnology Corp.

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Remeron

OOrganon and Co

Preclinical

1 6

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

REGN2810

1 10

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melanoma2 trials

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Completed·CCellxpert Biotechnology Corp.·Phase 1/2·NCT00073892·44 enrolled

Study of PI-88 in Patients With Advanced Melanoma

Completed·CCellxpert Biotechnology Corp.·Phase 1/2·NCT00068172·88 enrolled

Hepatocellular Carcinoma2 trials

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Terminated·PProgen Pharmaceuticals·Phase 3·NCT00568308·600 enrolled

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Completed·CCellxpert Biotechnology Corp.·Phase 2·NCT00247728·172 enrolled

Non-Small Cell Lung Cancer1 trial

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·CCellxpert Biotechnology Corp.·Phase 2·NCT00103389·98 enrolled

Lung Cancer1 trial

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Completed·CCellxpert Biotechnology Corp.·Phase 2·NCT00097851·100 enrolled

Prostate Cancer1 trial

Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

Completed·PProgen Pharmaceuticals·Phase 2·NCT00268593·48 enrolled

2 more indications

Metastatic Melanoma1 trial

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Completed·CCellxpert Biotechnology Corp.·Phase 2·NCT00130442·134 enrolled

Hepatitis1 trial

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection

Terminated·CCellxpert Biotechnology Corp.·Phase 3·NCT01402908·520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for PI-88. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PI-88 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PI-88. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cellxpert Biotechnology Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCellxpert Biotechnology Corp.

PI-88

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Melanoma2 trials

Hepatocellular Carcinoma2 trials

Non-Small Cell Lung Cancer1 trial

Lung Cancer1 trial

Prostate Cancer1 trial

Metastatic Melanoma1 trial

Hepatitis1 trial

References

Drug Info

Quick Facts

Related News